Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market worth USD 5.5 Bn by 2030 at a CAGR of 4.3%

The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market was valued at US$ 3.8 Bn in 2021 and is expected to reach US$ 5.5 Bn by 2030, finds Future Market Insights (FMI) in a recent market survey.

Sepsis, toxic shock syndrome, bacteremia, osteomyelitis, endocarditis, meningitis, pneumonia are amongst the life-threatening diseases caused by Staphylococcus Aureus bacteria. These diseases are cured by antibiotics.

Some form of staphylococcus aureus that has developed resistance to a broad range of antibiotics fall in the category of “Methicillin-Resistant Staphylococcus Aureus (MRSA)”. This resistance is one of the key factors driving the market in the near future as well as extensive research ought to be on the anvil to devise new medications.

According to FMI’s latest study, the rising incidences of MRSA all over the world are likely to create demand for safe and efficient drugs during the forecast period.

Covid-19 Pandemic: A Short-term Upholsterer

Outbreak of novel corona virus has resulted in short-term considerable increase in the number of MRSA infections. This number is expected to boost the market demand for MRSA antibiotics during the ongoing Covid-19 crisis. As per the latest data, around 2.5 million people have been infected by Covid-19 so far.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-10406

Key Takeaways of MRSA Treatment Market Study 

• In terms of drug class, glycopeptides (vancomycin) and oxazolidinones (linezolid) are collectively expected to account for over 75% of revenue share in the MRSA treatment market owing to preference of both antibiotic classes as a first-line treatment against MRSA infections and used in more than 80% of MRSA cases treatment.
• By route of administration, intravenous (IV) route of administration remains the recommended option. Drugs that can be administered through IV are likely to gain more than one-half of market share in the MRSA treatment market during the forecast period.
• By indication, skin and soft tissue infections (SSTIs) are leading the market and expected to gain more than 40% of revenue share followed by the pneumonia over the forecast period.
• Incidence of healthcare acquired MRSA is higher than community acquired MRSA, and FMI opines status-quo to remain unchanged during the assessment period
• North America is the highest revenue generating market by region due to high incidence of MRSA infections
• Asia Pacific is expected to witness high demand for MRSA testing systems due to high incidences of MRSA infection herein. For example – Journal of Family Medicine and Primary Care, in 2021, stated that occurrence of MRSA among kids aged 5 to 15 is between 16 and 52%. India alone accounts for 4-19% of these infections.

Government and Pharma Industry Focus on Working in Unison to Develop Advanced Treate  

As per University of Melbourne’s researchers, “Teixobactin” responds positively against MRSA. These results are likely to pave the way for development of antibacterial drugs to treat multi-drug resistant Gram-positive infections with thick cell wall. This will open wider doors for MRSA treatment market all over Australia and the other countries in Asia-Pacific. Teixobactin is already known for destroying Mycobacterium tuberculosis.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-10406

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market By Category

By Drug Class :

By Indication :

• Skin and Soft Tissue Infections (SSTIs)
• Pneumonia
• Bloodstream Infections
• Surgical and Medical Infections
• Others

By Route of Administration :

• Intravenous
• Oral
• Topical
• Nasal
• Cutaneous
• Intramuscular

By Type of MSRA :

• Healthcare Acquired MRSA
• Community Acquired MRSA
• Hospital Acquired MRSA

By Distribution Channel :

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

By Region :

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-10406

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact Us:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs